<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147946">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01855087</url>
  </required_header>
  <id_info>
    <org_study_id>R875</org_study_id>
    <nct_id>NCT01855087</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes</brief_title>
  <acronym>ASSIST-K</acronym>
  <official_title>A Study of Safety and Efficacy of Sitagliptin Added to Insulin Therapy in the Treatment of Type 2 Diabetes in Kanagawa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanagawa Physicians Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Kidney Foundation, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kanagawa Physicians Association</source>
  <oversight_info>
    <authority>Japan: Ethical Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is paucity of information about the combination therapy with dipeptidyl peptidase-4
      inhibitor sitagliptin and insulin. This study aimed to retrospectively investigate the
      safety and efficacy of this therapeutic modality in Japanese patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Blood glucose level</measure>
    <time_frame>Six months after starting sitagliptin-insulin combination therapy</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        One-thousand Japanese patients with type 2 diabetes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  outpatients with type 2 diabetes

          -  addition of sitagliptin to insulin therapy

          -  aged 20 years or older

          -  HbA1c of 6.9% or higher (NGSP) at the time of adding sitagliptin

        Exclusion Criteria:

          -  history of hypersensitivity to sitagliptin

          -  severe ketosis, diabetic coma, and/or precoma within 6 months before sitagliptin
             administration

          -  sever infection and/or severe trauma, and/or patients who are scheduled to undergo /
             have recently underwent surgery

          -  severe renal dysfunction (serum creatinine [mg/dL]: 2.5 or higher for men; 2.0 or
             higher for women)

          -  ongoing treatment with glinide(s)

          -  judgment as ineligible for the study by the attending physician
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 13, 2013</lastchanged_date>
  <firstreceived_date>May 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanagawa Physicians Association</investigator_affiliation>
    <investigator_full_name>Ikuro Matsuba</investigator_full_name>
    <investigator_title>Chairperson</investigator_title>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
